448 related articles for article (PubMed ID: 31067680)
21. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
22. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
25. Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy.
Wu J; Nie J; Luan Y; Ding Y
Curr Med Chem; 2023; 30(20):2267-2311. PubMed ID: 36043742
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
Garmpi A; Garmpis N; Damaskos C; Valsami S; Spartalis E; Lavaris A; Patelis N; Margonis GA; Apostolou KG; Spartalis M; Andreatos N; Diamantis E; Tsivelekas K; Moschos MM; Nonni A; Tsourouflis G; Markatos K; Antoniou EA; Kontzoglou K; Nikiteas N; Dimitroulis D
J BUON; 2018; 23(4):846-861. PubMed ID: 30358185
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Giannini G; Cabri W; Fattorusso C; Rodriquez M
Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
[TBL] [Abstract][Full Text] [Related]
29. Molecular probing and imaging of histone deacetylase inhibitors in cancer treatment.
Jiaguo H; Zhiguo L; Wenbin Z
Anticancer Agents Med Chem; 2012 Mar; 12(3):182-6. PubMed ID: 22044001
[TBL] [Abstract][Full Text] [Related]
30. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
32. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors: potent anti-leukemic agents.
Bian J; Zhang L; Han Y; Wang C; Zhang L
Curr Med Chem; 2015; 22(17):2065-74. PubMed ID: 25876840
[TBL] [Abstract][Full Text] [Related]
34. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors and rational combination therapies.
Grant S; Dai Y
Adv Cancer Res; 2012; 116():199-237. PubMed ID: 23088872
[TBL] [Abstract][Full Text] [Related]
36. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
37. Assays for pharmacodynamic analysis of histone deacetylase inhibitors.
Chung EJ; Lee MJ; Lee S; Trepel JB
Expert Opin Drug Metab Toxicol; 2006 Apr; 2(2):213-30. PubMed ID: 16866608
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Rodrigues DA; Pinheiro PSM; Sagrillo FS; Bolognesi ML; Fraga CAM
Med Res Rev; 2020 Nov; 40(6):2177-2211. PubMed ID: 32588916
[TBL] [Abstract][Full Text] [Related]
39. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
40. Targeting triple negative breast cancer with histone deacetylase inhibitors.
Fedele P; Orlando L; Cinieri S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
